Meridian Medical

Meridian Medical Technologies is a leading pharmaceutical and medical device company specializing in the development and manufacture of emergency auto-injector drug-device combination products. The company is most notably the manufacturer of the EpiPen, the global standard for emergency anaphylaxis treatment, and a primary provider of medical countermeasures for chemical nerve agent exposure to the U.S. Department of Defense. Meridian's expertise encompasses the entire lifecycle of rescue medications, from proprietary injector design to high-volume aseptic manufacturing and assembly. Formerly a division of Pfizer, the company was acquired by Altaris Capital Partners in 2022 and now operates as an independent entity focused on expanding its portfolio of rapid-response treatments for seizures, acute pain, and toxicological emergencies.